ImmuCell Reports Record Q1 2026 Earnings with $10M Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: seekingalpha
- Significant Revenue Growth: ImmuCell achieved $10.4 million in revenue for Q1 2026, marking its first quarter surpassing $10 million, which reflects strong performance in the calf scours market and boosts market confidence.
- Improved Gross Margins: The company reported a gross margin of 45%, up from 34% year-over-year, indicating successful production efficiency and pricing strategies that further solidify its competitive position in the industry.
- Market Share Expansion: ImmuCell's share in the U.S. calf scours prevention market increased from 29.1% to 35.2%, with the percentage of treated animals rising from 15% to 18.1%, demonstrating ongoing growth in market penetration.
- Funding for Expansion Plans: The company announced a $2 million settlement with a former contract manufacturer, intending to use these funds to expand production capacity to meet long-term demand, ensuring competitiveness in a rapidly growing market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCC
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NetSTREIT and ImmuCell Executives Increase Stock Holdings
- Executive Purchase: Mark Manheimer, President and CEO of NetSTREIT, bought 5,000 shares of NTST at $19.19 each on Thursday, totaling an investment of $95,950, indicating confidence in the company's future.
- Trading Performance: NTST reached a high of $19.57 during Monday's trading, with Manheimer's purchase showing a gain of approximately 2.0% at the peak, reflecting positive market sentiment towards the stock.
- Historical Buying: Previously, Manheimer purchased 100,436 shares at $17.93 each over the past 12 months, demonstrating his ongoing commitment to investing in the company's stock.
- ImmuCell Executive Purchase: Paul Francis Olivier te Boekhorst, CEO of ImmuCell, acquired 8,000 shares of ICCC at $9.49 each on Thursday, totaling $75,960, which reflects his optimistic outlook on the company's prospects.
See More
ImmuCell Reports Record Q1 2026 Earnings with $10M Revenue
- Significant Revenue Growth: ImmuCell achieved $10.4 million in revenue for Q1 2026, marking its first quarter surpassing $10 million, which reflects strong performance in the calf scours market and boosts market confidence.
- Improved Gross Margins: The company reported a gross margin of 45%, up from 34% year-over-year, indicating successful production efficiency and pricing strategies that further solidify its competitive position in the industry.
- Market Share Expansion: ImmuCell's share in the U.S. calf scours prevention market increased from 29.1% to 35.2%, with the percentage of treated animals rising from 15% to 18.1%, demonstrating ongoing growth in market penetration.
- Funding for Expansion Plans: The company announced a $2 million settlement with a former contract manufacturer, intending to use these funds to expand production capacity to meet long-term demand, ensuring competitiveness in a rapidly growing market.
See More
ImmuCell Reports Strong Q1 Earnings with 28.4% Revenue Growth
- Earnings Highlights: ImmuCell reported a GAAP EPS of $0.21 for Q1, indicating a sustained enhancement in profitability, which reflects the company's competitive position and attractiveness to investors.
- Revenue Growth: The company achieved revenue of $10.36 million in Q1, representing a robust 28.4% year-over-year increase, demonstrating success in product sales and market expansion, thereby strengthening future growth expectations.
- Cash Flow Improvement: As of March 31, 2026, cash and cash equivalents rose to $6.8 million from $3.8 million as of December 31, 2025, indicating a significant improvement in liquidity that supports future investments and operations.
- Net Asset Increase: Stockholders' equity increased to $29.1 million as of March 31, 2026, up from $27.1 million as of December 31, 2025, reflecting an improvement in the company's financial health and boosting investor confidence.
See More
ImmuCell Appoints New Board Members to Enhance Strategy
- New Board Appointments: ImmuCell has appointed Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, aiming to leverage their extensive experience in animal health to enhance the company's strategic capabilities, which is expected to drive innovation and technology development.
- Formation of Strategy and Technology Committee: The newly established Strategy and Technology Committee will be chaired by Guillemette, focusing on supporting management's efforts to improve production efficiency and expand capacity, thereby driving innovation growth for the First Defense® product line.
- Increased Independent Board Representation: The board will consist of seven members, with six being independent, a structural change that not only enhances corporate governance but also provides stronger support for future mergers and strategic decisions.
- Executive Retirements and Successions: Bryan Gathagan and other non-independent board members will retire on April 15, 2026, ensuring the independence and professionalism of corporate governance while continuing to support daily operations for a smooth transition.
See More
ImmuCell Q1 Sales Surge 28.4% Driven by Tri-Shield Demand
- Total Sales Growth: ImmuCell's Q1 total product sales reached $10.4 million, reflecting a 28.4% increase compared to the same period in 2025, indicating a significant performance boost driven by strong market demand.
- Domestic Sales Performance: Domestic sales in 2026 amounted to $9.7 million, a 35.7% increase from 2025, demonstrating the company's sustained competitiveness in the domestic market and further solidifying its market position.
- International Sales Challenges: Despite robust domestic sales, international sales in 2026 were only $0.6 million, a 30.2% decline from 2025, highlighting challenges in the international market that could impact overall growth potential moving forward.
- Product Line Performance: Tri-Shield sales reached $7.9 million, up 38.5%, while Dual Force and other products generated $2.5 million in sales, a 4.4% increase, showcasing strong demand for Tri-Shield as a key driver of overall sales growth.
See More
ImmuCell Reports 28.4% Revenue Growth in Q1 2026
- Strong Sales Performance: ImmuCell Corporation reported preliminary net sales of $10.4 million for Q1 2026, reflecting a 28.4% increase from $8.1 million in the same quarter last year, indicating robust performance in the animal health biologics sector.
- Tri-Shield Product Growth: Sales of the Tri-Shield product surged by 38.5% to $7.9 million, primarily driven by seasonal demand in the cow-calf segment, which further solidifies the company's market position in the industry.
- Strategic Product Line: ImmuCell's flagship product line, First Defence, targets the treatment of scours, a prevalent disease among neonatal calves, effectively improving calf survivability and health, which is crucial for the company's market relevance.
- Future Outlook: The company anticipates a shift in demand towards year-round dairy customers in the second and third quarters, showcasing the adaptability and growth potential of its products, and plans to host a conference call on May 15, 2026, to discuss unaudited financial results.
See More
NetSTREIT and ImmuCell Executives Increase Stock Holdings
- Executive Purchase: Mark Manheimer, President and CEO of NetSTREIT, bought 5,000 shares of NTST at $19.19 each on Thursday, totaling an investment of $95,950, indicating confidence in the company's future.
- Trading Performance: NTST reached a high of $19.57 during Monday's trading, with Manheimer's purchase showing a gain of approximately 2.0% at the peak, reflecting positive market sentiment towards the stock.
- Historical Buying: Previously, Manheimer purchased 100,436 shares at $17.93 each over the past 12 months, demonstrating his ongoing commitment to investing in the company's stock.
- ImmuCell Executive Purchase: Paul Francis Olivier te Boekhorst, CEO of ImmuCell, acquired 8,000 shares of ICCC at $9.49 each on Thursday, totaling $75,960, which reflects his optimistic outlook on the company's prospects.
See More
ImmuCell Reports Record Q1 2026 Earnings with $10M Revenue
- Significant Revenue Growth: ImmuCell achieved $10.4 million in revenue for Q1 2026, marking its first quarter surpassing $10 million, which reflects strong performance in the calf scours market and boosts market confidence.
- Improved Gross Margins: The company reported a gross margin of 45%, up from 34% year-over-year, indicating successful production efficiency and pricing strategies that further solidify its competitive position in the industry.
- Market Share Expansion: ImmuCell's share in the U.S. calf scours prevention market increased from 29.1% to 35.2%, with the percentage of treated animals rising from 15% to 18.1%, demonstrating ongoing growth in market penetration.
- Funding for Expansion Plans: The company announced a $2 million settlement with a former contract manufacturer, intending to use these funds to expand production capacity to meet long-term demand, ensuring competitiveness in a rapidly growing market.
See More
ImmuCell Reports Strong Q1 Earnings with 28.4% Revenue Growth
- Earnings Highlights: ImmuCell reported a GAAP EPS of $0.21 for Q1, indicating a sustained enhancement in profitability, which reflects the company's competitive position and attractiveness to investors.
- Revenue Growth: The company achieved revenue of $10.36 million in Q1, representing a robust 28.4% year-over-year increase, demonstrating success in product sales and market expansion, thereby strengthening future growth expectations.
- Cash Flow Improvement: As of March 31, 2026, cash and cash equivalents rose to $6.8 million from $3.8 million as of December 31, 2025, indicating a significant improvement in liquidity that supports future investments and operations.
- Net Asset Increase: Stockholders' equity increased to $29.1 million as of March 31, 2026, up from $27.1 million as of December 31, 2025, reflecting an improvement in the company's financial health and boosting investor confidence.
See More
ImmuCell Appoints New Board Members to Enhance Strategy
- New Board Appointments: ImmuCell has appointed Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, aiming to leverage their extensive experience in animal health to enhance the company's strategic capabilities, which is expected to drive innovation and technology development.
- Formation of Strategy and Technology Committee: The newly established Strategy and Technology Committee will be chaired by Guillemette, focusing on supporting management's efforts to improve production efficiency and expand capacity, thereby driving innovation growth for the First Defense® product line.
- Increased Independent Board Representation: The board will consist of seven members, with six being independent, a structural change that not only enhances corporate governance but also provides stronger support for future mergers and strategic decisions.
- Executive Retirements and Successions: Bryan Gathagan and other non-independent board members will retire on April 15, 2026, ensuring the independence and professionalism of corporate governance while continuing to support daily operations for a smooth transition.
See More
ImmuCell Q1 Sales Surge 28.4% Driven by Tri-Shield Demand
- Total Sales Growth: ImmuCell's Q1 total product sales reached $10.4 million, reflecting a 28.4% increase compared to the same period in 2025, indicating a significant performance boost driven by strong market demand.
- Domestic Sales Performance: Domestic sales in 2026 amounted to $9.7 million, a 35.7% increase from 2025, demonstrating the company's sustained competitiveness in the domestic market and further solidifying its market position.
- International Sales Challenges: Despite robust domestic sales, international sales in 2026 were only $0.6 million, a 30.2% decline from 2025, highlighting challenges in the international market that could impact overall growth potential moving forward.
- Product Line Performance: Tri-Shield sales reached $7.9 million, up 38.5%, while Dual Force and other products generated $2.5 million in sales, a 4.4% increase, showcasing strong demand for Tri-Shield as a key driver of overall sales growth.
See More
ImmuCell Reports 28.4% Revenue Growth in Q1 2026
- Strong Sales Performance: ImmuCell Corporation reported preliminary net sales of $10.4 million for Q1 2026, reflecting a 28.4% increase from $8.1 million in the same quarter last year, indicating robust performance in the animal health biologics sector.
- Tri-Shield Product Growth: Sales of the Tri-Shield product surged by 38.5% to $7.9 million, primarily driven by seasonal demand in the cow-calf segment, which further solidifies the company's market position in the industry.
- Strategic Product Line: ImmuCell's flagship product line, First Defence, targets the treatment of scours, a prevalent disease among neonatal calves, effectively improving calf survivability and health, which is crucial for the company's market relevance.
- Future Outlook: The company anticipates a shift in demand towards year-round dairy customers in the second and third quarters, showcasing the adaptability and growth potential of its products, and plans to host a conference call on May 15, 2026, to discuss unaudited financial results.
See More
